Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Tvardi Therapeutics (TVRD) Tax Provisions (2016 - 2020)

Tvardi Therapeutics' Tax Provisions history spans 8 years, with the latest figure at -$255000.0 for Q4 2020.

  • On a quarterly basis, Tax Provisions changed N/A to -$255000.0 in Q4 2020 year-over-year; TTM through Sep 2021 was -$255000.0, a 66.71% increase, with the full-year FY2024 number at -$398000.0, changed N/A from a year prior.
  • Tax Provisions hit -$255000.0 in Q4 2020 for Tvardi Therapeutics, down from -$132000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for TVRD hit a ceiling of -$2000.0 in Q2 2017 and a floor of -$330000.0 in Q3 2019.
  • Historically, Tax Provisions has averaged -$126421.1 across 5 years, with a median of -$125000.0 in 2018.
  • Biggest five-year swings in Tax Provisions: surged 97.47% in 2017 and later tumbled 7500.0% in 2018.
  • Tracing TVRD's Tax Provisions over 5 years: stood at -$189000.0 in 2016, then surged by 86.24% to -$26000.0 in 2017, then plummeted by 380.77% to -$125000.0 in 2018, then tumbled by 164.0% to -$330000.0 in 2019, then increased by 22.73% to -$255000.0 in 2020.
  • Business Quant data shows Tax Provisions for TVRD at -$255000.0 in Q4 2020, -$132000.0 in Q3 2020, and -$182000.0 in Q2 2020.